skip to main content

Translational Research

A major focus of the Terry Fox Research Institute is translational research. Translation is often defined as research which moves discoveries made in the clinic to the laboratory and thence back to the bedside.  It is sometimes called “applied” research. This area of research holds great promise today for providing improved care and outcomes for cancer patients everywhere. Translational research is focused on speeding up the development and adoption of new treatments and technologies for the benefit of cancer patients and their families, the healthcare system and for the population at large. It covers the spectrum of cancer research from early detection and screening to diagnosis, treatment and monitoring of treatment. Translational research has been underfunded in the past partly because it is complex, involves many different disciplines and stakeholders, and is usually expensive to do. 

Please refer to the table below for the current portfolio of TFRI translational projects. Additional information for each can be found in the Canadian Research Information System (CRIS) database.

Current Opportunities

A Strategic Opportunity for the TFRI Translational Program is now launched annually. The 2018 Strategic Opportunity will be announced in mid-April, 2017.

Previous Funding Competition

The 2017 Strategic Opportunity is closed to applications.

Meeting Reports

Below are meeting reports from recent meetings and workshops related to our translational research projects.

Pancreatic Cancer Workshop Meeting Report - September 2015
Myeloma Workshop Meeting Report - July 2015

List of Translational Cancer Research Projects


Pan-Canadian Colorectal Cancer Consortium (C4)

Batist, G; Gallinger, S
Therapeutic Targeting of Glioblastoma (with Alberta Cancer Foundation, Alberta Innovates, Genome Canada and others)

Cairncross, G

Biomarker driven management of Prostate Cancer Phase II
Saad, F
FV-guided surgical trial for Oral Cancer control
Durham, S; Poh, C; Rosin, M
Sub-type management of Ovarian Cancer (with CPAC)
Mes-Masson, A-M; Huntsman, D; Provencher, D

  Project  Start/End      Lead
Selective Therapies Program Collaboration: Therapeutic Targets Validation in Ovarian Cancer 2012-2016 Mes-Masson, A-M / Rottapel, R
PRecision Oncology For Young peopLE (PROFYLE)
2016-2017 Malkin, David
National Science Council (NSC) of Taiwan - TFRI Scientific Collaborations
  Project  Start/End      Lead
The Development of New Treatments and Biomarkers for Hepatocellular Carcinoma: from Woodchuck to Human 2013-2016 Bell, J / Chen, P-J
Development of 2-[18F]fluoro-2-deoxy-D-galactose as a new molecular imaging probe for hepatocellular carcinoma diagnosis 2013-2016 Benard, F / Kai-Yuan, T
Investigation of the Pathogenesis of ASXL1 mutation in acute myeloid leukemia 2013-2016 Humphries, Keith / Karsan, A / Tien, H-F / Kuo, Y-Y / Chou, W-C
Translational Research in Lung Cancer: from Molecular Markers / Targets to Therapeutic Applications 2013-2016 Lam, S / Lam, W / Yang, P-C / Yu, C-J
Back to Top